| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/08/2004 | US20040005361 Pharmaceutical preparations |
| 01/08/2004 | US20040005360 Core-and-shell dosage form or unit in which the core contains API and in which the shell substantially governs the release such as by controlling diffusion of API through the shell. The shell may comprise a release-blocking polymer, and particles |
| 01/08/2004 | US20040005359 Controlled release oral dosage form |
| 01/08/2004 | US20040005358 Formulation is provided which is capable of releasing vasopeptidase inhibitor, preferably omapatrilat or gemopatrilat, in a manner to provide therapeutically effective NEP inhibitory activity and therapeutically effective ACE |
| 01/08/2004 | US20040005357 Extended-release tablets comprising divalproex sodium |
| 01/08/2004 | US20040005356 Paroxetine which is formulated into tablets using a formulation process in which water is absent. |
| 01/08/2004 | US20040005355 Synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, a heavily sulfated |
| 01/08/2004 | US20040005354 Oral trimethobenzamide formulations and methods |
| 01/08/2004 | US20040005353 Delivery system for antisense oligonucleotides involves a liposomal composition, comprising a liposome which consists essentially of neutral phospholipids and an antisense oligonucleotide that is entrapped in the liposome and is |
| 01/08/2004 | US20040005351 Cosolvent evaporation methods and compositions for improving the solubility of hydrophobic compounds, including therapeutic agents such as anticancer drugs, polyene antibiotics, antilipidemic agents, and hydrophobic compounds, |
| 01/08/2004 | US20040005347 Composition and a method for the treatment of mood disorders, in particular of treating, preventing or alleviate depression, mood disorders or insufficient mood, obesity, overweight, premenstrual syndrome, craving, carbohydrate |
| 01/08/2004 | US20040005345 Formulation for transmucosal vaginal delivery of bisphosphonates. A targeted site delivery of bisphosphonates to the systemic circulation using a vaginal device comprising an improved bisphosphonate formulation for transmucosal |
| 01/08/2004 | US20040005342 Topical administration of ascorbic acid to reinforce the cohesion of the dermo-epidermal junction |
| 01/08/2004 | US20040005339 Fibrate oral formulation with improved bioavailability when compared to commercially available formulations containing a therapeutically effective dose of fenofibrate or a fenofibrate derivative dissolved in N-alkyl derivative of 2-pyrrolidone, |
| 01/08/2004 | US20040005315 Administering an immunosuppressive agent that depletes T cells and anti-alpha beta T cell receptor antibodies, and implanting an allograft into the recipient. |
| 01/08/2004 | US20040005313 Use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role |
| 01/08/2004 | US20040005311 Including a core of lysine and bromelain and, optionally, including lycopene; can be used to alleviate dementia-related symptoms. |
| 01/08/2004 | US20040005308 Composition and method for treating non-bacterial prostatitis |
| 01/08/2004 | US20040005307 Modulators of amyloid aggregation |
| 01/08/2004 | US20040005306 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 01/08/2004 | US20040005305 Nutritional composition for treating an immune condition |
| 01/08/2004 | US20040005304 Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions |
| 01/08/2004 | US20040005303 In vivo induction for enhanced function of isolated hepatocytes |
| 01/08/2004 | US20040005291 Modulating antigen specific immune responses, treating autoimmune diseases, such as multiple sclerosis, and cancer, and for modulating cell growth. |
| 01/08/2004 | US20040004037 Direct osmotic hydration devices |
| 01/08/2004 | DE10227793A1 Stabilisierte Cholinascorbat enthaltende Zusammensetzung Stabilized choline-containing composition |
| 01/08/2004 | DE10227668A1 Arzneimittel zur Behandlung des systemic inflammatory response syndrome Drugs for the treatment of systemic inflammatory response syndrome |
| 01/08/2004 | DE10227511A1 Mittel zur medikamentösen Behandlung von akuten und chronischen Schmerzen Means for drug treatment of acute and chronic pain |
| 01/08/2004 | DE10227508A1 Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung Acid group-substituted Diphenylazetidinones, processes for their preparation, pharmaceutical compositions containing them and their use |
| 01/08/2004 | DE10227507A1 Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung Cationically substituted Diphenylazetidinones, processes for their preparation, pharmaceutical compositions containing them and their use |
| 01/08/2004 | DE10227506A1 Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung Ring-substituted Diphenylazetidinones, processes for their preparation, pharmaceutical compositions containing them and their use |
| 01/08/2004 | DE10227269A1 Thiazolderivate Thiazole derivatives |
| 01/08/2004 | DE10227155A1 Glucan mit TNFα -Ausschüttung induzierender Wirkung, Verfahren zu dessen Herstellung und dieses enthaltende pharmazeutische Zubereitungen Glucan with TNF.alpha -Ausschüttung inducing activity, to processes for its preparation and pharmaceutical compositions containing this |
| 01/08/2004 | DE10227148A1 Verwendung von Ribavirin zur Herstellung einer pharmazeutischen Zusammensetzung gegen Bunyaviridae The use of ribavirin for the manufacture of a pharmaceutical composition against Bunyaviridae |
| 01/08/2004 | DE10226943A1 Phenylaminopyrimidine und ihre Verwendung Phenylaminopyrimidine and their use |
| 01/08/2004 | DE10226814A1 Neue Arzneimittelkombinationen zur Behandlung ischämischer Zustände New drug combinations for the treatment of ischemic conditions |
| 01/08/2004 | DE10226700A1 Verwendung von Astaxathin Use of Astaxathin |
| 01/08/2004 | DE10226592A1 Tumorhemmende Platin(II)-oxalato-Komplexe Antitumor platinum (II) complexes -oxalato |
| 01/08/2004 | DE10226494A1 Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen Film form mucoadhesive dosage forms for administration of cannabis drugs |
| 01/08/2004 | DE10226459A1 Verwendung von Dopamin-Partialagonisten zur Behandlung des Restless Legs Syndroms Use of dopamine partial agonists for the treatment of Restless Legs Syndrome |
| 01/08/2004 | DE10226203A1 Kondensierte Palatinose und Verfahren zu deren Herstellung Condensed palatinose and processes for their preparation |
| 01/08/2004 | DE10224844A1 Nicht-peptidische BRS-3-Agonisten Non-peptidic BRS-3 agonist |
| 01/08/2004 | DE10224556A1 1-Dimethylamino- 3-(3-methoxy-phenyl)2-methyl-pentan-3-ol entaltendes Arzneimittel in verschiedenen Formulierungen 1-dimethylamino-3- (3-methoxy-phenyl) 2-methyl-pentan-3-ol entaltendes drug in different formulations |
| 01/08/2004 | DE10057290B4 Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten To be administered enterally supplement for parenteral nutrition or partial enteral / oral nutrition in critically ill patients, chronically ill and malnourished |
| 01/08/2004 | DE10012026B4 Verwendung eines Gels Use of a gel |
| 01/08/2004 | CA2844639A1 Method for the treatment of multiple sclerosis |
| 01/08/2004 | CA2744893A1 Aryl carbonyl derivatives as glucokinase activators |
| 01/08/2004 | CA2672551A1 Biodegradable block copolymeric compositions for drug delivery |
| 01/08/2004 | CA2513143A1 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers |
| 01/08/2004 | CA2500165A1 Drug composition containing nf-.kappa.b inhibitor |
| 01/08/2004 | CA2494249A1 Novel azasugar derivative and drug containing the same as the active ingredient |
| 01/08/2004 | CA2493854A1 Phosphodiesterase inhibitor |
| 01/08/2004 | CA2493646A1 Caspase inhibitors and uses thereof |
| 01/08/2004 | CA2492084A1 Carvedilol hydobromide |
| 01/08/2004 | CA2492080A1 Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
| 01/08/2004 | CA2492066A1 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 01/08/2004 | CA2492065A1 Aminoalcohol derivatives_as b3 adrenergic receptor agonist |
| 01/08/2004 | CA2491549A1 Method of promoting smoking cessation |
| 01/08/2004 | CA2491543A1 Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability |
| 01/08/2004 | CA2491427A1 Compositions and methods for therapeutic treatment |
| 01/08/2004 | CA2491271A1 2-(phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses |
| 01/08/2004 | CA2491156A1 Inhibitors of hcv ns5b polymerase |
| 01/08/2004 | CA2491118A1 A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof |
| 01/08/2004 | CA2491094A1 Method for determination of likelihood of occurrence of preterm labor in pregnant females |
| 01/08/2004 | CA2491089A1 Compounds useful for the inhibition of aldh |
| 01/08/2004 | CA2491034A1 Methods and materials for treating human papillomavirus infections |
| 01/08/2004 | CA2491002A1 Combination of pde5 inhibitors with angiotensin ii receptor antagonists |
| 01/08/2004 | CA2490950A1 Inhibitors of hcv ns5b polymerase |
| 01/08/2004 | CA2490811A1 Use of organic compounds |
| 01/08/2004 | CA2490804A1 Method of treating autoimmune diseases with interferon-beta and il-2r antagonist |
| 01/08/2004 | CA2490688A1 Therapeutic agent for brain hemorrhage |
| 01/08/2004 | CA2490683A1 Coating suspensions (comprising osmopolymers, osmagents) for forming an expandable osmotic composition in controlled release dosage forms as well as the corresponding method for providing this osmotic coating |
| 01/08/2004 | CA2490547A1 Disinfecting composition |
| 01/08/2004 | CA2490412A1 Oral dosage from comprising a liquid active agent formulation and controlling release thereof by an expandable osmotic composition |
| 01/08/2004 | CA2490367A1 Therapeutic methods for reducing fat deposition and treating associated conditions |
| 01/08/2004 | CA2490298A1 Porphyrin-polyamine conjugates for cancer therapy |
| 01/08/2004 | CA2490253A1 Novel adenosine analogues and their use as pharmaceutical agents |
| 01/08/2004 | CA2490250A1 Drug composition for blood sugar control |
| 01/08/2004 | CA2490193A1 Glycoloyl-substituted oxazolidinone-derivatives as antibacterial agents |
| 01/08/2004 | CA2490138A1 Novel tetrahydropyridine derivatives as renin inhibitors |
| 01/08/2004 | CA2490130A1 Combination comprising a vasculostatic compound and an alkylating agent for the treatment of a tumor |
| 01/08/2004 | CA2490129A1 Compositions and methods comprising protein activated receptor antagonists |
| 01/08/2004 | CA2489771A1 Biodegradable block copolymeric compositions for drug delivery |
| 01/08/2004 | CA2489688A1 Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton |
| 01/08/2004 | CA2489682A1 Method for the separation of triglycoalkaloids |
| 01/08/2004 | CA2489675A1 Glycoalkaloid compositions and various uses thereof |
| 01/08/2004 | CA2489660A1 Drug composition for prevention or inhibition of advance of diabetic complication |
| 01/08/2004 | CA2489560A1 Substituted quinoline ccr5 receptor antagonists |
| 01/08/2004 | CA2489555A1 Camptothecin-carboxylate formulations |
| 01/08/2004 | CA2489552A1 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| 01/08/2004 | CA2489428A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 01/08/2004 | CA2489411A1 Difluorothioacetamides of oxazolidinones as antibacterial agents |
| 01/08/2004 | CA2489376A1 Methods of organ regeneration |
| 01/08/2004 | CA2489295A1 Spherical pellet containing a water-soluble active ingredient |
| 01/08/2004 | CA2488703A1 Food and beverage product for stimulating gastrointestinal mobility |
| 01/08/2004 | CA2488566A1 Use of an alpha2delta ligand such as gabapentin or pregabalin for treating attention deficit hyperactivity disorder |
| 01/08/2004 | CA2488526A1 Stable liquid parenteral parecoxib formulation |
| 01/08/2004 | CA2488525A1 Morpholine and tetrahydropyran derivatives and their use as cathepsin inhibitors |
| 01/08/2004 | CA2488039A1 A pharmaceutical composition for preventive and/or therapeutic treatment of constipation and symptom resulting from constipation |
| 01/08/2004 | CA2487712A1 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |